Skip to main content
. 2017 Jul 12;10(5):719–725. doi: 10.1016/j.tranon.2017.06.004

Figure 2.

Figure 2

Kaplan-Meier survival curves for OS according to inflammation-based scores in 226 patients with acral melanoma. (A) Ninety-four patients with NLR ≥2.35 had shorter median OS than 132 patients with NLR <2.35 (39.4 vs 55 months, P=.047). (B) One hundred two patients with PLR ≥129 had shorter median OS than 124 patients with PLR <129 (40.9 vs 62 months, P=.01). (C) One hundred eight patients with SII ≥615×109/l had shorter median OS than 118 patients with SII <615×109/l (34 vs 62 months, P=.006). (D) One hundred four patients with CTII ≥0.08 had shorter median OS than 122 patients with CTII <0.08 (40 vs 68.4 months, P=.044). (E) ROC curves of NLR, PLR, SII, CTII, and AJCC M stage for OS, with a median survival time of 47.2 months.